Ritchie Craig W, Bridgeman Katie, Gregory Sarah, O'Brien John T, Danso Samuel O, Dounavi Maria-Eleni, Carriere Isabelle, Driscoll David, Hillary Robert, Koychev Ivan, Lawlor Brian, Naci Lorina, Su Li, Low Audrey, Mak Elijah, Malhotra Paresh, Manson Jean, Marioni Riccardo, Murphy Lee, Ntailianis Georgios, Stewart William, Muniz-Terrera Graciela, Ritchie Karen
Edinburgh Dementia Prevention, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, EH4 2XU, UK.
Scottish Brain Sciences, Edinburgh, EH12 9DQ, UK.
Brain Commun. 2024 May 31;6(3):fcae189. doi: 10.1093/braincomms/fcae189. eCollection 2024.
PREVENT is a multi-centre prospective cohort study in the UK and Ireland that aims to examine midlife risk factors for dementia and identify and describe the earliest indices of disease development. The PREVENT dementia programme is one of the original epidemiological initiatives targeting midlife as a critical window for intervention in neurodegenerative conditions. This paper provides an overview of the study protocol and presents the first summary results from the initial baseline data to describe the cohort. Participants in the PREVENT cohort provide demographic data, biological samples (blood, saliva, urine and optional cerebrospinal fluid), lifestyle and psychological questionnaires, undergo a comprehensive cognitive test battery and are imaged using multi-modal 3-T MRI scanning, with both structural and functional sequences. The PREVENT cohort governance structure is described, which includes a steering committee, a scientific advisory board and core patient and public involvement groups. A number of sub-studies that supplement the main PREVENT cohort are also described. The PREVENT cohort baseline data include 700 participants recruited between 2014 and 2020 across five sites in the UK and Ireland (Cambridge, Dublin, Edinburgh, London and Oxford). At baseline, participants had a mean age of 51.2 years (range 40-59, SD ± 5.47), with the majority female ( = 433, 61.9%). There was a near equal distribution of participants with and without a parental history of dementia (51.4% versus 48.6%) and a relatively high prevalence of APOEɛ4 carriers ( = 264, 38.0%). Participants were highly educated (16.7 ± 3.44 years of education), were mainly of European Ancestry ( = 672, 95.9%) and were cognitively healthy as measured by the Addenbrookes Cognitive Examination-III (total score 95.6 ± 4.06). Mean white matter hyperintensity volume at recruitment was 2.26 ± 2.77 ml (median = 1.39 ml), with hippocampal volume being 8.15 ± 0.79 ml. There was good representation of known dementia risk factors in the cohort. The PREVENT cohort offers a novel data set to explore midlife risk factors and early signs of neurodegenerative disease. Data are available open access at no cost via the Alzheimer's Disease Data Initiative platform and Dementia Platforms UK platform pending approval of the data access request from the PREVENT steering group committee.
“预防痴呆症研究项目（PREVENT）”是一项在英国和爱尔兰开展的多中心前瞻性队列研究，旨在研究痴呆症的中年风险因素，并识别和描述疾病发展的最早指标。“预防痴呆症研究项目”是最初针对中年这一神经退行性疾病关键干预窗口的流行病学倡议之一。本文概述了研究方案，并展示了初始基线数据的首批总结结果以描述该队列。“预防痴呆症研究项目”队列的参与者提供人口统计学数据、生物样本（血液、唾液、尿液以及可选的脑脊液）、生活方式和心理问卷，接受全面的认知测试组合，并使用多模态3-T磁共振成像扫描进行成像，包括结构序列和功能序列。文中描述了“预防痴呆症研究项目”队列的管理结构，其中包括一个指导委员会、一个科学咨询委员会以及核心患者和公众参与小组。还介绍了一些补充主要“预防痴呆症研究项目”队列的子研究。“预防痴呆症研究项目”队列的基线数据包括2014年至2020年期间在英国和爱尔兰的五个地点（剑桥、都柏林、爱丁堡、伦敦和牛津）招募的700名参与者。基线时，参与者的平均年龄为51.2岁（范围40 - 59岁，标准差±5.47），大多数为女性（n = 433，61.9%）。有或没有痴呆症家族史的参与者分布近乎相等（51.4%对48.6%），且APOEɛ4携带者的患病率相对较高（n = 264，38.0%）。参与者受教育程度较高（平均受教育年限16.7 ± 3.44年），主要为欧洲血统（n = 672，95.9%），根据Addenbrookes认知测试-III（总分95.6 ± 4.06）测量认知健康。入组时平均脑白质高信号体积为2.26 ± 2.77毫升（中位数 = 1.39毫升），海马体体积为8.15 ± 0.79毫升。该队列中已知的痴呆症风险因素具有良好的代表性。“预防痴呆症研究项目”队列提供了一个新的数据集，用于探索中年风险因素和神经退行性疾病的早期迹象。通过阿尔茨海默病数据倡议平台和英国痴呆症平台可免费开放获取数据，但需等待“预防痴呆症研究项目”指导小组委员会批准数据访问请求。
